Dharmacon RNAi Technology Selected by Genentech to support Drug Discovery Research
"We think it is fitting that Dharmacon, a pioneer in RNAi research, has been selected by Genentech, one of the world's leading biotechnology companies, to supply advanced siRNA products and technology for its drug discovery research programs, " said Leland Foster, president and chief executive officer of the Biosciences group of Fisher Scientific International Inc. "We believe this agreement is further indication that Dharmacon's SMARTselection and SMARTpool technologies are a preferred gene-silencing platform for drug discovery research among leading pharmaceutical and biotechnology companies. Dharmacon's continued leadership in the RNAi field and the exceptional potency and specificity of our siRNA reagents make us the supplier of choice for researchers utilizing RNAi technology to accelerate drug discovery."
Most read news
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.